INDIANAPOLIS, July 6, 2016 /PRNewswire/ — Crystal Bowersox understands how crucial it is to properly manage diabetes and find a healthy balance on and off the stage. It’s so important that people know how to reduce their risk of developing Type 2 diabetes, that they know about the symptoms and that they know how to manage the condition if they have it. Having nearly lost her spot on the show due to a short hospitalization brought on by the rigorous taping and rehearsal schedule, she vowed to make it her mission to touch others impacted by diabetes with her music and her message. Instead, she announced yesterday, she is partnering “with a reputable pharmaceutical company” as spokesperson for a $500-a-month diabetes drug (with side-effects that may include pancreatitis and thyroid cancer). In this role, Crystal will speak to children with diabetes at summer camps and other events, sharing her story and inspiring them to reach for their dreams. Her ambassadorship is one
Copyright 2015 Fields Law Office, Ltd., a Lipitor lawsuit settlements law firm. Lipitor, the popular cholesterol drug, has been linked to an increased risk of diabetes, particularly in middle-aged and older women. It is a member of the statin class of hypolipidemics and was approved by the FDA in December of 1996. In 2012, the FDA ordered Pfizer, the makers of Lipitor, to add warning labels about the increased risk for diabetes. Our Lipitor attorneys are investigating whether the manufacturer of Lipitor was aware of diabetes side effects prior to the FDA’s study, and whether the company knowingly or negligently put patients at risk. Over 21 million Americans rely on Lipitor and other statins, including one in four Americans over the age of 45. Some people who take statins are perfectly healthy, but are taking the drugs as preventative medicine.
Food and Drug Administration released a drug safety communication reporting serious health risks for patients using statins, such as Lipitor
Coexistence of Charcot Marie Tooth disease type 1A and diabetes in Taiwan: A clinicopathological study.
Charcot neuroarthropathy (CN) is a disabling and devastating condition that affects many neuropathic diabetic patients. Seeking all three essential bone growth properties for successful bone remodeling and repair—osteoinductive, osteoconductive, and osteogenic—has been a complex task; however, they are essential in difficult surgical situations with poor host bone tissue. Controls were individually matched for gender, age (+/-2 years), disease type, disease duration (+/-2 years) and year of referral (+/-3 years). The single most significant discovery relative to diabetic foot ulceration is the role of peripheral sensory neuropathy. Assessment of neuropathy was carried out by checking the sense of pressure, joint position and vibration. The most effective treatment, however, is prevention. We found three patients with CN of the knee (all female; patient A: 25 years old, type 1 diabetes for 10 years, HbA1c was 11.6% [103 mmol/mol]; patient B: 26 years old, type 1 diabetes
Retinal Function In Patients With Isquemic Diabetic Retinopathy Using Full-field Electroretinogram | IOVS
Abstract Prognostic studies were made on a series of 101 juvenile diabetics (onset before the age of 30 years) who developed late diabetic manifestations in the form of retinopathy and/or proteinuria between 1944 and 1958 and in whom the beginning of these manifestations could be dated with reasonable accuracy. PDR patients with light perception (LP) or hand movement (HM) acuity due to severe vitreous hemorrhage require vitreous surgery. The purpose of this study was to determine whether the visual acuity of PDR patients with LP or HM can be graded into finer steps with the Low Vision Evaluator (LoVE). By superimposing the OCT pattern over the mfERG hexagonal pattern, hexagons corresponding to the OCT pattern were identified (D). The study included 51 patients with DR and CKD; of these, 11 patients (21.6%) were found to have proliferative DR (PDR) and seven patients (13.7%) had high-risk PDR at baseline. The median age of at the time of notification of VI for the three